IMPEDIMED LIMITED — Annual Report 2014

Aug 26, 2014

27 August 2014

==> picture [103 x 99] intentionally omitted <==

----- Start of picture text -----

ASX: IPD
----- End of picture text -----

ASX ANNOUNCEMENT

APPENDIX 4E – FINANCIAL YEAR ENDED 30 JUNE 2014

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“the Company”), is pleased to provide its Appendix 4E, Preliminary Final Report for the financial year ended 30 June 2014.

ImpediMed continued its sales growth momentum recording $3.58 million of revenue from ordinary activities for the financial year. Lymphoedema revenue grew 34% compared to the prior financial year. Full year loss reduced by $0.53 million to $7.94 million.

President and CEO Richard Carreon stated, “We enter financial year 2015 in a very strong position as we gear up our sales and marketing activities in preparation for the CPT[®] Category I code (government pay code) coming into effect on 01 Jan 2015.”

Richard Carreon CEO

ENDS For further information contact:

Richard Carreon, ImpediMed CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: www.impedimed.com.au

Page 1 of 1

Appendix 4E Preliminary final report Period ending 30 June 2014

ImpediMed Limited - Appendix 4E ABN 65 089 705 144 Preliminary final report

• 1 Current Financial Period Ended: 30 June 2014 Previous Corresponding Reporting Period: 30 June 2013

The information contained in this document should be read in conjunction with the ImpediMed Limited Annual Financial Report for the year ended 30 June 2014 ("2014 Financial Report") and any public announcements made by ImpediMed Limited and its controlled entities during the year in accordance with continuous disclosure obligations arising under the ASX Listing Rules.

• 2 Results for announcement to the market

Previous Current reporting corresponding period period $000 $000 2.1 Revenue from ordinary activities $ (3,578) $ (2,925) Increase (decrease) in revenue ($000): $ 653 Percentage increase (decrease): 22%

Note : Revenue related to goods and services increased for the year ended 30 June 2014 to $3.5 million (2013 $2.7 million), an increase of $0.8 million year over year. The change by operating segment was an increase of $0.6 million in medical, and a $0.2 million increase in Test & Measurement (T&M). The $0.6 million increase in the medical segment was due to a $0.2 million increase in body composition and veterinary products, while total lymphoedema product revenue for the Group increased by $0.4 million, or 34% year over year. 2.2 Profit/(loss) from ordinary activities after tax attributable to members (7,935) (8,464) Increase/(decrease) in profit from ordinary activities after tax attributable to members ($000): $ 529 Percentage increase/(decrease): 6% Note : Refer to the Directors' Report for a more extensive analysis; however, in summary, in addition to the increase in revenue above: - salaries and benefits expense decreased by $0.2 million - rent and property costs decreased by $0.1 million - travel expense increased by $0.2 million - consultants and professional fees increased by $0.1 million - other expense decreased by $0.1 million 2.3 Net profit/(loss) for the period attributable to members (7,935) (8,464) Increase/(decrease) in net profit for the period attributable to members ($000): $ 529 Percentage increase/(decrease): 6% Note: Refer to 2.2 above and to the Directors' Report in the 2014 Financial Report. 3 Dividends 3.1 Dividends Nil There were no dividends declared and paid during the reporting period on ordinary shares. There were no dividends proposed and not yet recognised as a liability during the reporting period. 3.2 Dividend Record Date Not applicable

Appendix 4E Preliminary final report Period ending 30 June 2014

4 Financial Statements

4.1 Statement of comprehensive income

Refer to the Consolidated Statement of Comprehensive Income in the 2014 Financial Report.

4.2 Statement of financial position

Refer to the Consolidated Balance Sheet in the 2014 Financial Report.

4.3 Statement of cash flows

Refer to the Consolidated Cash Flow Statement in the 2014 Financial Report.

4.4 Statement of retained earnings

Refer to the Consolidated Statement of Changes in Equity in the 2014 Financial Report for movements in retained earnings.

• 5 Net tangible assets per security

					Previous
		Current reporting			corresponding
			period		period
5.1	Net tangible assets ($000)		11,567		8,560
	Issued share capital at reporting date ($000)		116,593		106,101
					Previous
		Current reporting			corresponding
			period		period
	Number of shares on issue at reporting date		238,672,802		181,314,055
	Net tangible assetsper security	$	0.05	$	0.05
6	Earnings per security
					Previous
		Current reporting			corresponding
			period		period
6.1	Weighted average number of ordinary shares (excluding		195,605,935		181,229,055
	reserved shares) for basic earnings per share (EPS)
	Loss per share from continued operations
	Basic EPS	$	(0.04)	$	(0.05)
	Loss per share from profit attributable to ordinary shares
	Basic EPS	$	(0.04)	$	(0.05)
	Diluted earnings per share has been determined to be the	same as basic earnings per share as
	the actual calculation is anti-dilutive for both periods presented.
	Refer to Note 12 - Earnings per share in the Annual Financial Report for the year ended 30
	June 2014 for additional informationpertainingto EPS for the current reporting period.
7	Acquisitions and divestments
	There were no entities over which control has beengained or lost duringthe reporting period.
8	Foreign entities
	Not applicable.
9	Associates and joint ventures
	Not applicable.
10	Commentary on results for the financial year
	Refer to the Annual Financial Report for the year ended 30 June 2014.
11	Results of segments
	Refer to Note 6 - Segment reporting in the Annual Financial Report for the year ended 30 June
	2014 for additional information pertaining to segment results for		the current reporting period.
12	Audited Report
	The report is based on audited accounts which are not subject to dispute, modification, or qualification.